National TB control program Flashcards
What is the National Strategic Plan (NSP) for TB control 2016-2020
- vision?
Vision:
Msia free of TB by year 2035
- Aim to reduce TB death (compared to 2015) by 95% & reduced TB incidence by 90% [<10 per 100 000 population] (compared to 2015)
What is the National Strategic Plan (NSP) for TB control 2016-2020
- goal?
Goal: Decrease the burden of TB by
1) Ensuring universal access to timely and quality Dx & Rx of all forms of TB
2) Prevent development of DRTB in the country
What is the National Strategic Plan (NSP) for TB control 2016-2020
- target?
Target:
Target by 2020:
1) TB mortality reduced by 25%
2) TB notification rate increase to 100 per 100 000 population
3) Universal access to Dx & Rx of all forms of TB inc MDR & XDRTB (at least 90% of MDRTB are successfully treated)
What is the National Strategic Plan (NSP) for TB control 2016-2020
- 11 strategies?
Strategy 1: Enhance case detection of TB
Strategy 2: Improve control of TB among children
Strategy 3: Decrease the burden of TB/HIV in ppl at risk of or affected by both disease
Strategy 4: Strengthen Programmatic Mx of DR-TB
Strategy 5: Strengthen laboratory network to find all TB cases
Strategy 6: Strengthen Programmatic Mx of LTBI activities
Strategy 7: Enhance BCG vax program
Strategy 8: Ensure uninterrupted supply of quality-assured TB drugs
Strategy 9: Enable supportive environment & systems for effective TB control
Strategy 10: Ensure no households that experience catastrophic cost due to TB
Strategy 11: Intensify research & innovation as priority issues in TB control program
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 1: Enhance case detection of TB?
Strategy 1: Enhance case detection of TB
Key indicators:
1) Increase case notification from 75 (in 2015) to 100 per 100 000 population by 2020
2) Symptomatic screening: 2000 per 100 000 population by 2020
3) Contact screening coverage at 1st visit >90% and at 4th visit >50%
4) Treatment success rate >90%
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 2: Improve control of TB among children
Strategy 2: Improve control of TB among children
Key indicators:
1) Increase case detection from 3.1% to 5% in 2020
2) Achieve Rx success to 95% for peads cases
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 3: Decrease the burden of TB/HIV in ppl at risk of or affected by both disease
Strategy 3: Decrease the burden of TB/HIV in ppl at risk of or affected by both disease
Key indicators:
1) # new or relapse TB in documented HIV/ # of new or relapse TB = 100%
2) # HIV on LTBI Rx/ # of eligible cases = 90%
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 4: Strengthen Programmatic Mx of DR-TB
Strategy 4: Strengthen Programmatic Mx of DR-TB
Key indicators:
1) MDRTB cases notification <3% of all TB cases
2) Rx success rate of DR-TB >90%
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 5:
Strengthen laboratory network to find all TB cases
Strategy 5:
Strengthen laboratory network to find all TB cases
Key indicators:
1) Drug susceptibility test coverage 100%
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 6: Strengthen Programmatic Mx of LTBI activities
children <5yo of household treated for LTBI started on LTBI Rx/ # eligible ppl for Rx >50%
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 7: Enhance BCG vax program
Strategy 7: Enhance BCG vax program
Key indicators:
BCG coverage for newborns >98%
Re: BCG vax
- 70-80% effective against most severe form of TB e.g. TB meningitis in children, which lasted 10-15y
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 8: Ensure uninterrupted supply of quality-assured TB drugs
Strategy 8: Ensure uninterrupted supply of quality-assured TB drugs
Key indicators:
Ensure uninterrupted supply of quality-assured TB drugs
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 9: Enable supportive environment & systems for effective TB control
Strategy 9: Enable supportive environment & systems for effective TB control
Key indicators:
1) # of TB pt referred by community volunteers/NGOs for TB Dx & Rx
2) #of TB pt under f/up or DOT with community volunteers/NGOs
3) # TB pt cured/ completed TB Rx under supervision of community volunteers/ NGOs
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 10: Ensure no households that experience catastrophic cost due to TB
Strategy 10: Ensure no households that experience catastrophic cost due to TB
Key indicator: not specified in guideline
What is the National Strategic Plan (NSP) for TB control 2016-2020
- key indicators for Strategy 11: Intensify research & innovation as priority issues in TB control program
Strategy 11: Intensify research & innovation as priority issues in TB control program
Key indicator:
Establishment of TB research network
What are the three elements of the National Strategic Plan (NSP) for TB control 2016-2020?
1) Integrated, pt-centred care & prevention (Strategies 1-7)
- early Dx inc drug-susceptibility test & screening of contacts & high-risk groups
- Rx all Tb inc DRTB
- collaborative TB/HIV activities & Mx of comorbidities
- preventive Rx of persons at high risk & vax against TB
2) Bold policies and supportive systems (Strategies 8-10)
- Political commitment with adequate resources for TB care & prevention
- engagement with communities, public/ private care providers
- universal health cover age policy, and regulatory frame work for case notification, vital registration, quality and rational use of meds & infection control
- Social protection, poverty alleviation & actions on other determinants of TB
3) Intensified research & innovation (Strategy 11)
- discovery, development and rapid uptake of new tools, interventions & strategies
- research to optimise implementation & impact, and promote innovations
What is the available TB screening program?
1) Contact tracing of index case
- 4 visits in total: (0,3,6,12-m interval)
1st visit at 0 month
2nd visit at 3m after 1st visit
3rd visit at 6m after 2nd visit
4th visit at 12m after 3rd visit
2) Screening of high risk group
- High risk group:
i) contact of index TB case
ii) TB/HIV comorbid
iii) inmate for prisons/ cure & care rehab centre
iv) DM
v) smokers
vi) ESRF on HD
vii) pt taking TNFi
viii) COPD
ix) elderly
x) on methadone therapy/ under substance abuse clinic
3) Screening of TB in prison (at entry & regular screening)
What are the challenges in TB Mx in Malaysia?
1) Low case detection of TB & MDR-TB
2) Resources available not parallel with disease burden
3) Low TB case detection among children
4) Insufficient TB-HIV collaborative activities
5) Inadequate policy for LTBI Rx
6) Inadequate knowledge & awareness re BCG vax
7) Poor TB Rx outcomes
8) Lack of adequate engagement of communities in active TB finding & Rx adherence
9) Lack of TB support groups & policy to address social determinants of pts
10) Inadequate research & innovations in TB program
Case definition
1) Bacteriologically confirmed TB
- one from whom a biological specimen is positive by smear microscopy, culture or WHO-recommend rapid diagnostic tests (e.g. GeneXpert)
- all such cases should be notified, regradless whether TB Rx has started
2) Clinically diagnosed TB
- one who does not fulfil the criteria for bacteriological confirmation but has been diagnosed with active TB by a clinician or other medical practitioner who has decided to give the pt a full course of TB Rx.
- includes cases diagnosed on basis of abnorm X-ray, or suggestive of HPE and extrapulmonary cases w/out lab confirmation.
- Clinically diagnosed cases subsequently found to be bacteriologically positive (before or after starting Rx) should be reclassified as bacteriologically confirmed.
TB cases are also classified according to:
a) anatomical site of disease
b) Hx of previous Rx
c) drug resistance
d) HIV status
Bacteriologically confirmed TB cases are classified according to:
a) anatomical site of disease
b) Hx of previous Rx
c) drug resistance
d) HIV status
Anatomical site of disease:
1) Pulmonary TB (PTB):
- involving lung parenchyma or tracheobronchial tree
- miliary TB
- both PTB and EPTB should be classified as PTB
###TB intrathoracic lymphadenopathy or pleural TB without radiographic abnorm in the lungs is considered EPTB##
2) Extrapulmonary TB (EPTB)
- involving organs other than lungs e.g. pleural, lymph nodes, abdo, GUT, skin, joints and bones, meninges.
Bacteriologically confirmed TB cases are classified according to:
a) anatomical site of disease
b) Hx of previous Rx
c) drug resistance
d) HIV status
Hx of previous Rx:
this classification is independent of bacteriologically confirmed or site of disease
1) New pt:
- never been treated for TB or have taken ATT for <1m
2) Previously treated pt:
- have received ≥1m ATT in the past
- this group is further classified by the outcome of their most recent course of Rx:
a) Relapse pt:
- previously treated for TB were decleared cured or Rx completed at the end of their most recent course of Rx
- and are now diagnosed with recurrent episode of TB
- (either true relapse or a new episode of TB caused by reinfection)
b) Rx after failure pt:
- previously treated for TB, and whose Rx failed at the end of their most recent course of Rx
c) Rx after loss to follow-up pt:
- Previously treated for TB and were declared loss to f/up at the end of their most recent course of Rx
d) Other previously treated pt:
- Those who have previously been treated for TB but whose outcome after their most recent course of Rx is unknown or undocumented
New & relapse cases of TB are incident TB cases
Bacteriologically confirmed TB cases are classified according to:
a) anatomical site of disease
b) Hx of previous Rx
c) drug resistance
d) HIV status
Drug resistance:
1) Monoresistance: resistant to one 1st line ATT
2) Polydrug resistance: resistant to >1 1st line ATT (apart from both H & R)
3) Multidrug resistance: resistant to at least both H & R
4) Extensive drug resistance:
Previously: resistant to fluoroquinolone + injectable drugs + H + R
Currently: resistant to H+R+ fluoroquinolones + Bedaquiline or Linezolid
5) Rifampicin resistance: resistant to R
Bacteriologically confirmed TB cases are classified according to:
a) anatomical site of disease
b) Hx of previous Rx
c) drug resistance
d) HIV status
HIV status
What are ‘incident TB cases’?
New & relapse cases of TB are incident TB cases